Renovaro INC 10-K annual reports

Lunai Bioworks Inc. reported a significant increase in net loss for fiscal year 2025, alongside a subsidiary's bankruptcy and ongoing legal challenges, raising substantial doubt about its ability to continue as a going concern.

Renovaro Inc. restated its 2024 financial statements due to a material misstatement related to the accounting for warrant exercises, impacting the fair value of contingent consideration.

Renovaro Inc. has filed an amendment to its annual report to include required information on directors, executive compensation, and a new clawback policy.

Renovaro Inc.'s 10-K filing details a year of significant financial losses, strategic realignment towards AI-driven diagnostics, and ongoing efforts to secure additional funding.